Ligand Pharmaceuticals has acquired XOMA Royalty Corporation for an undisclosed amount. XOMA Royalty Corporation is a biotechnology royalty aggregator that plays a distinctive role in helping biotech companies achieve their goal of improving human health. The company acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires these future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes.
This acquisition significantly expands Ligand's portfolio of biotechnology assets. XOMA Royalty has an extensive and growing portfolio of royalty and milestone assets, defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate. These assets represent future potential payment streams from a basket of drug products in development. For Ligand, this transaction provides immediate access to a diversified collection of these rights, enhancing its strategic position within the pharmaceutical and biotechnology landscape.
The strategic rationale behind Ligand's purchase of XOMA Royalty centers on strengthening its revenue streams and diversifying its asset base without incurring direct drug development costs. By integrating XOMA's established royalty aggregation model and its existing portfolio, Ligand aims to capitalize on the future commercialization success of numerous therapeutic candidates across various stages of development. This move is expected to generate long-term value by leveraging XOMA's unique approach to acquiring future economic rights.
The combination of Ligand Pharmaceuticals and XOMA Royalty Corporation creates an entity with a more robust and diversified collection of biotechnology assets. This acquisition is poised to enhance Ligand's ability to generate sustainable revenue from a broader array of potential future payment streams, reinforcing its commitment to the biotechnology sector. The combined entity is expected to benefit from the expanded portfolio, driving future growth and value creation.